Podcasts about Staphylococcus

Karl Matthews, Ph.D., Professor of Microbial Food Safety at Rutgers University, discusses ways to eliminate pathogens like Salmonella, E. coli O157:H7 and Listeria from fresh fruits and vegetables. He highlights the importance of preventative measures from farm to table, including the use of water antimicrobials, like chlorine, and photosensitizers, like curcumin. Watch this episode: https://youtu.be/6Wkef9RyUVE Ashley's Biggest Takeaways We consume billions of microorganisms in the food that we eat each day. Fresh fruits and vegetables that are not thermally processed are likely to carry a higher microbial load than cooked foods. Many of those microbes are not concerning to human health. However, when pathogens of human health concern are present, the food can become unsafe to eat. Scientists use many methods from pre-harvest through post-harvest to keep food free of human pathogens. Water antimicrobials, such as chlorine, and photodynamic inactivation using photosensitizers, such as curcumin, are 2 preventative measures that Matthews and colleagues are investigating. Curcumin is a natural chemical compound found in the turmeric plant. It is responsible for giving tumeric its yellow color. Curcumin is also a photosensitizer, meaning that it can absorb light energy and transfer it to another molecule to initiate chemical reactions that produce cytotoxic singlet oxygen. Featured Quotes When I look at [what makes fruits and vegetables safe to eat] as far as from a microbiological perspective, it's are they free of pathogens of human health concern? And so, we might think about organisms, such as Salmonella or the Shiga toxin producing E coli or Listeria. There are a number of processes and initiatives that are put into place, from the pre-harvest through post-harvest levels to try to ensure that the product is not contaminated with microorganisms of human health concern. Each day, we're consuming literally billions of microorganisms in the foods that we eat, and particularly the raw fruits and vegetables that we're eating that are not being thermally processed in any fashion by which you might reduce the microbial load. Oftentimes we think about the bacteria that might well be there. But we do know that there's viruses that could be present. There's certain type of protozoa that might be present. Many of us know of norovirus and the concerns associated with that particular pathogen. So, there's a multitude of microorganisms that might well be associated with fresh fruits and vegetables, but there's really a very limited number or types that are actually of concern from a human health standpoint. In my program, we're working on E. coli O157:H7, in particular. It's a certain serotype of E. coli, a diarrheagenic E. coli, what's also known as a Shiga toxin-producing E. coli. We work with Salmonella, and we work with Listeria monocytogenes, but there's other microorganisms, such as Campylobacter, Yersinia, Staphylococcus aureus. All of those types of pathogens can also be associated with foods—and different types of foods, at that—and be of concern to the general public—the consumer. If we look at a lot of the processing of foods that are taking place, not only here in the United States, but globally, many times, what will happen is they're utilizing some type of a water antimicrobial, and I stress that because, oftentimes, these antimicrobials are added to the water to control the microbial load in the water. So, ultimately, you're not basically putting on water and putting on a whole load of microorganisms along with it. And also, you can prevent cross contamination through that. Here in the U.S. and elsewhere, we'll often put additional chlorine into the water. So, let's say we're increasing the chlorine concentration to 20 parts per million, or 50 parts per million, or maybe in poultry processing, they're utilizing peracetic acid. These are 2 common antimicrobials that are being used. What we wanted to do is find out could we utilize some other types of methods that might well control microorganisms on the commodity itself? And that's where we started looking at photodynamic inactivation and coupling that with the use of a photosensitizer. And in this particular case, the photosensitizer we were using was curcumin. The reason for working with curcumin is that it's naturally used in foods as a food dye. It's also used as a flavoring agent, and so forth. So, it's there, and it's being used—not just in the U.S., but [also] globally. And we thought we would try to see if we utilize this compound, could we have an additive effect to it? If you apply certain wavelengths of light, you can inactivate microorganisms, but if you apply that wavelength to something like a photosensitizer type molecule (curcumin), you could generate singlet oxygen molecules. And those singlet oxygen molecules would act like little explosions on the cell membrane and basically blow it apart and, therefore, inactivate the organism. We looked at the ability of this to inactivate Listeria monocytogenes, Salmonella, as well as E. coli O157:H7, so these Shiga toxin-producing E. coli, and what we did indeed find is that it was very effective. We looked at it in comparison to peracetic acid use in the poultry industry, and we found it to be equivalent, at least to treatments that we were utilizing on poultry skin, with inactivation of the microorganisms, such as Listeria, on the poultry skin. So, it is really exciting. Links for This Episode ​​​​​​Preventing Foodborne Outbreaks Starts in the Field. Influences of photosensitizer curcumin on microbial survival and physicochemical properties of chicken during storage.

Le “triangle de la mort” désigne une zone du visage comprise entre l'arête du nez et les commissures des lèvres, formant un triangle. Cette appellation spectaculaire vient d'une particularité anatomique : dans cette région, les veines superficielles (veine faciale, veine angulaire) communiquent directement avec des veines profondes de l'orbite (veines ophtalmiques) et, au-delà, avec le sinus caverneux, une grande veine située à la base du crâne. Or ces veines sont dépourvues de valvules efficaces, ce qui autorise un reflux du sang vers le crâne en cas d'inflammation, de pression ou d'infection locales.Concrètement, une lésion cutanée banale du triangle — bouton manipulé, poil incarné, gerçure, furoncle dans le vestibule nasal — peut, très rarement, permettre à des bactéries (souvent Staphylococcus aureus, parfois streptocoques ou anaérobies) de gagner la circulation veineuse puis le sinus caverneux. Cela expose à une thrombose du sinus caverneux (formation d'un caillot infecté), à une méningite ou à un abcès intracrânien. Ces complications restent exceptionnelles à l'ère des antibiotiques, mais leur gravité explique la réputation de cette zone.Les signes d'alarme qui doivent faire consulter en urgence après une infection du nez ou de la lèvre supérieure sont : fièvre, céphalée intense, douleur autour d'un œil, œdème palpébral, rougeur conjonctivale, diplopie (vision double), douleur aux mouvements oculaires, proptose (œil “qui ressort”), diminution de la vision, engourdissement du front ou de la joue (atteinte des nerfs V1/V2), voire paralysie oculomotrice (nerfs III, IV, VI). Le diagnostic repose sur l'examen clinique et l'imagerie (IRM avec angio-IRM ou TDM), et le traitement associe antibiothérapie intraveineuse rapide, prise en charge en milieu spécialisé, parfois anticoagulation selon les cas.Pourquoi le risque augmente-t-il quand on “triture” un bouton ? En pressant, on provoque microtraumatismes et diffusion bactérienne dans des tissus très vascularisés, avec un gradient de pression qui peut favoriser la remontée du sang vers les veines profondes. Le risque est majoré par le diabète, l'immunodépression, une sinusite non traitée ou une infection dentaire maxillaire.Les gestes de prévention sont simples : éviter de percer ou manipuler les lésions dans cette zone ; nettoyer la peau avec une solution douce ; traiter les croûtes/sécheresses nasales (salines isotoniques, baumes adaptés) ; consulter en cas de douleur, fièvre, extension de la rougeur, écoulement purulent nasal, ou atteinte de l'œil. En résumé, le “triangle de la mort” n'est pas une fatalité : c'est le rappel qu'ici, la connexion veineuse directe avec l'intérieur du crâne impose de respecter les règles d'hygiène et de ne pas jouer les dermatologues amateurs. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Antimicrobial resistance (AMR) continues to grow as a global health threat, making infections harder to treat and leaving fewer options for patients. The need for new antibiotics is an urgent matter — but traditional discovery methods are slow and limited. In this episode of Let's Talk Micro, Luis is joined by Dr. James Collins, professor at MIT and researcher at the Broad Institute, who is leading efforts to apply AI to antibiotic discovery. We discuss how his team used deep learning to uncover promising new compounds, including NG1 and DN1, which showed activity against drug-resistant Neisseria gonorrhoeae and Staphylococcus aureus. We also talk about the challenges of bringing discoveries from computer models to the clinic, and what this approach could mean for the future of the fight against superbugs.   Link to study: https://www.cell.com/cell/abstract/S0092-8674%2825%2900855-4   Check out the website: https://www.letstalkmicro.com/ Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro  

À l'ère du smartphone et du télétravail, les écouteurs font désormais partie de notre quotidien. Que ce soit pour écouter de la musique, téléphoner ou suivre une visioconférence, ils restent des heures durant dans nos oreilles. Mais ce geste anodin est-il sans risque pour notre santé ? Plus précisément, peut-il favoriser l'apparition d'otites ?La réponse est oui, dans certains cas. Les spécialistes ORL s'accordent sur un point : l'usage prolongé et répété d'écouteurs intra-auriculaires peut créer un environnement propice aux infections, en particulier les otites externes, c'est-à-dire les inflammations du conduit auditif.Une étude publiée en 2008 dans le Journal of Laryngology and Otology (par Leong et al.) a comparé le conduit auditif de deux groupes : un groupe portant régulièrement des écouteurs, et un groupe n'en utilisant jamais. Résultat : les utilisateurs fréquents d'écouteurs présentaient un taux significativement plus élevé de bactéries pathogènes, notamment Staphylococcus aureus et Pseudomonas aeruginosa, des germes souvent impliqués dans les otites externes.Pourquoi ce lien entre écouteurs et otites ? Plusieurs mécanismes sont en cause :1. Obstruction du conduit auditif : les écouteurs, surtout intra-auriculaires, empêchent la bonne ventilation du canal. L'humidité naturelle ne s'évacue pas correctement, créant un terrain chaud et humide, idéal pour la prolifération des bactéries.2. Microtraumatismes : le frottement régulier des embouts ou leur insertion brutale peut irriter la peau du conduit, facilitant l'entrée des agents infectieux.3. Manque d'hygiène : peu d'utilisateurs nettoient leurs écouteurs régulièrement. Or, ces dispositifs sont souvent posés sur des surfaces non stériles ou partagés entre plusieurs personnes. Les germes présents sur les écouteurs peuvent ainsi être introduits dans l'oreille à chaque usage.Les symptômes d'une otite externe liée aux écouteurs sont classiques : douleurs, démangeaisons, rougeur du conduit auditif, voire écoulement. Dans certains cas, l'audition peut temporairement diminuer. Si ces signes apparaissent, il est recommandé d'arrêter immédiatement l'usage des écouteurs et de consulter un médecin.Pour limiter les risques, quelques gestes simples suffisent :Ne pas porter d'écouteurs plus de deux heures d'affilée.Les désinfecter régulièrement avec un chiffon doux imbibé d'alcool à 70 %.Éviter de les partager.Aérer ses oreilles entre deux utilisations.En conclusion, si les écouteurs ne sont pas à l'origine directe de toutes les otites, leur usage excessif et négligent peut en augmenter la probabilité, notamment en cas de mauvaise hygiène. Pour écouter en toute sécurité, mieux vaut penser aussi à… laisser respirer ses oreilles. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Episode Notes Join DASON Clinical Pharmacist Liaison Jeannette Bouchard as she speaks with Dr. Nick Turner, lead author of the DOTS randomized clinical trial, about the potential of dalbavancin as a simplified treatment for Staphylococcus aureus bacteremia. They discuss the trial's findings, its implications for clinical practice, and whether two doses can truly replace weeks of IV antibiotics. The materials reviewed in this episode can be found here: https://dason.medicine.duke.edu/blog/new-rules-old-infections-what-dots-trial-tells-us For more information about DASON, please visit: https://dason.medicine.duke.edu

On episode #87 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/31/25 – 8/18/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Bacterial Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Propensity-Matched Comparison of Timely vs. Delayed Antibiotic Therapy in Stenotrophomonas maltophilia Pneumoni (OFID) The proportion of Treponema pallidum PCR-positive primary syphilis infections which are seronegative for syphilis (OFID) Cefixime versus benzathine penicillin G for the treatment of early syphilis (Journal of Antimicrobial Chemotherapy) Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Fungal The Last of US Season 2 (YouTube) Parasitic Increasing Length of the Babesia Season in New England in the Climate Change Era (OFID) Ivermectin to Control Malaria (NEJM) Miscellaneous ACIP Recommendations Summary (CDC: Influenza) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En 1928, Alexander Fleming, un bacteriólogo escocés, realizó uno de los descubrimientos médicos más importantes de la historia: la penicilina. Mientras trabajaba en el Hospital St. Mary’s de Londres, Fleming notó que una placa de cultivo de bacterias Staphylococcus aureus había sido contaminada por un moho de color verde. Observó detenidamente lo que había sucedido y advirtió que, alrededor del moho, las bacterias no crecían, lo que indicaba que el moho producía una sustancia que las inhibía. Este moho fue bautizado como Penicillium notatum, y la sustancia, como penicilina. Esto marcó el inicio de la era de los antibióticos. Aunque Fleming publicó sus hallazgos en 1929, no pudo purificar la penicilina ni producirla a gran escala. Fue en la década de 1940 cuando científicos como Ernst Chain y Howard Florey lograron aislar y estabilizar el compuesto, permitiendo su uso médico. La industria farmacéutica estadounidense hizo el resto. Durante la Segunda Guerra Mundial, la penicilina salvó innumerables vidas al tratar infecciones bacterianas en soldados lo que supuso toda una revolución para la medicina. El descubrimiento de Fleming fue accidental, pero su observación meticulosa y su curiosidad científica las bases para un avance que transformó el tratamiento de enfermedades infecciosas. La penicilina no solo redujo la mortalidad por infecciones, sino que también abrió la puerta al desarrollo de otros antibióticos. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! En 1928, Alexander Fleming, un bacteriólogo escocés, realizó uno de los descubrimientos médicos más importantes de la historia: la penicilina. Mientras trabajaba en el Hospital St. Mary’s de Londres, Fleming notó que una placa de cultivo de bacterias Staphylococcus aureus había sido contaminada por un moho de color verde. Observó detenidamente lo que había sucedido y advirtió que, alrededor del moho, las bacterias no crecían, lo que indicaba que el moho producía una sustancia que las inhibía. Este moho fue bautizado como Penicillium notatum, y la sustancia, como penicilina. Esto marcó el inicio de la era de los antibióticos. Aunque Fleming publicó sus hallazgos en 1929, no pudo purificar la penicilina ni producirla a gran escala. Fue en la década de 1940 cuando científicos como Ernst Chain y Howard Florey lograron aislar y estabilizar el compuesto, permitiendo su uso médico. La industria farmacéutica estadounidense hizo el resto. Durante la Segunda Guerra Mundial, la penicilina salvó innumerables vidas al tratar infecciones bacterianas en soldados lo que supuso toda una revolución para la medicina. El descubrimiento de Fleming fue accidental, pero su observación meticulosa y su curiosidad científica las bases para un avance que transformó el tratamiento de enfermedades infecciosas. La penicilina no solo redujo la mortalidad por infecciones, sino que también abrió la puerta al desarrollo de otros antibióticos. · Canal de Telegram: https://t.me/lacontracronica · “Contra la Revolución Francesa”… https://amzn.to/4aF0LpZ · “Hispanos. Breve historia de los pueblos de habla hispana”… https://amzn.to/428js1G · “La ContraHistoria de España. Auge, caída y vuelta a empezar de un país en 28 episodios”… https://amzn.to/3kXcZ6i · “Lutero, Calvino y Trento, la Reforma que no fue”… https://amzn.to/3shKOlK · “La ContraHistoria del comunismo”… https://amzn.to/39QP2KE Apoya La Contra en: · Patreon... https://www.patreon.com/diazvillanueva · iVoox... https://www.ivoox.com/podcast-contracronica_sq_f1267769_1.html · Paypal... https://www.paypal.me/diazvillanueva Sígueme en: · Web... https://diazvillanueva.com · Twitter... https://twitter.com/diazvillanueva · Facebook... https://www.facebook.com/fernandodiazvillanueva1/ · Instagram... https://www.instagram.com/diazvillanueva · Linkedin… https://www.linkedin.com/in/fernando-d%C3%ADaz-villanueva-7303865/ · Flickr... https://www.flickr.com/photos/147276463@N05/?/ · Pinterest... https://www.pinterest.com/fernandodiazvillanueva Encuentra mis libros en: · Amazon... https://www.amazon.es/Fernando-Diaz-Villanueva/e/B00J2ASBXM #FernandoDiazVillanueva #penicilina #fleming Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.Related Content: Dalbavancin for Treatment of Staphylococcus aureus BacteremiaManagement of Staphylococcus aureus Bacteremia

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia

No episódio de hoje do Check-up Semanal, nosso editor-chefe médico, Ronaldo Gismondi, traz as principais atualizações do último mês sobre Clínica Médica publicadas no Portal Afya.Confira os temas do episódio:- Diretrizes para ajuste de antibioticoterapia em pacientes obesos;- Câncer de sítio primário oculto: ainda vale buscar o local de origem?;- Roteiro estratégico para investigação de diarreia aguda e crônica;- Quando indicar antibióticos na pancreatite aguda;- Ecocardiograma transesofágico na bacteremia por Staphylococcus aureus: sempre necessário?Aperte o play e ouça agora os destaques que impactam a prática clínica na atenção ao paciente adulto!

Cauda Equina Syndrome • Neurosurgical emergency due to compression of cauda equina nerve roots, usually from disc herniation, tumor, or trauma Clinical Presentation Labs, Studies, and Physical Exam Findings Treatment Key Differentiators Epidural Abscess • • Spinal epidural infection commonly caused by Staphylococcus aureus Clinical Presentation Labs, Studies, and Physical Exam Findings Treatment Key Differentiators […] The post 131 Neuro: Spinal Cord issues appeared first on Physician Assistant Exam Review.

On episode #85 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/3 – 7/21/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Elimination of HIV Reservoirs Harboring Intact Proviruses (JID) Bacterial Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024 (NEJM) Study hints doxyPEP use coincides with rise in tetracycline-resistant gonorrhea in US (CIDRAP) Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus (CID) Methenamine hippurate asprophylaxis for recurrent urinary tract infections in older women – a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU). (CMI: Clinical Microbiology and Infection) Diagnosis and Management ofCommunity-acquired Pneumonia(American Journal of Respiratory and Critical Care Medicine) Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management (IDSA) The impact of an intervention to increase follow-up blood cultures for patients with Staphylococcus aureus bacteriuria (Antimicrobial Stewardship & Healthcare Epidemiology) Fungal The Last of US Season 2 (YouTube) Candida auris Containment Responses in Health Care Facilities that Provide Hemodialysis Services (CDC: MMWR) Candidozyma auris: an emerging threat (Reflections on Infectious Prevention and Control) Effects of postoperative antifungal therapy on the recurrence of Aspergillus infection after pulmonary aspergilloma resection (BMC Infectious Diseases) Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study (LANCET: Microbe) Large language models and their performance for the diagnosis of histoplasmosis (PLoS Neglected Tropical Diseases) Parasitic Field evidence of Trypanosoma cruzi infection, diverse host use and invasion of human dwellings by the Chagas disease vector in Florida, USA (PLoS Neglected Tropical Diseases) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Dr. Don and Professor Ben talk about the risks of making pancakes from old sourdough leftovers. Fedica text: Dr. Don - not risky

Is it time to rethink how we treat atopic dermatitis?Atopic dermatitis is more than skin deep—and naturopath and award-winning clinician Rebecca Hughes is here to prove it. In this practical and insightful episode, Rebecca shares her integrative, root-cause approach to eczema that goes far beyond suppressing symptoms with topical steroids.Drawing from extensive clinical experience, Rebecca highlights the importance of accurate diagnosis, noting that conditions such as psoriasis, seborrheic dermatitis, and lupus are often misidentified as eczema—leading to ineffective treatment. She walks practitioners through key investigations, from food intolerance and intestinal permeability testing to genetic susceptibilities, that help identify true inflammatory drivers.Rebecca also outlines her foundational nutrient protocol, including zinc, vitamin D, vitamin A, quercetin, and glutamine, and discusses how these work synergistically to modulate immune response, stabilise mast cells, and repair gut integrity. She also addresses overlooked environmental triggers like mould and water-damaged buildings, as well as the clinical importance of emotional support, sleep hygiene, and managing the psychological toll of visible skin conditions.Clinicians will find practical strategies for supporting patients through topical steroid withdrawal, tips on using bleach baths safely for Staphylococcus aureus overgrowth, and why children with eczema require particularly vigilant care.With a soon-to-be-released practitioner course on atopic dermatitis, Rebecca equips healthcare professionals with the tools they need to treat this complex condition confidently and holistically.Connect with Rebecca: Home - Rebecca Hughes Naturopath Explore Rebecca's Managing Atopic Dermatitis Course: Use code SAVE30 for a 30% discount. More information on the course can be found here: Managing Atopic Dermatitis | Natural Skin Medicine CoursesGet in touch! Shownotes and references are available on the Designs for Health websiteRegister as a Designs for Health Practitioner and discover quality practitioner- only supplements at www.designsforhealth.com.au Follow us on Socials Instagram: Designsforhealthaus Facebook: Designsforhealthaus DISCLAIMER: The Information provided in the Wellness by Designs podcast is for educational purposes only; the information presented is not intended to be used as medical advice; please seek the advice of a qualified healthcare professional if what you have heard here today raises questions or concerns relating to your health

Story at-a-glance Your scalp hosts a dense microbial ecosystem that protects against inflammation and disease. When disrupted, it can lead to flaking, itching, thinning hair, and inflammatory scalp conditions like seborrheic dermatitis The scalp microbiome is dominated by key bacteria like Cutibacterium acnes and Staphylococcus epidermidis. These microbes help protect your skin barrier, manage inflammation, and regulate other harmful organisms Scalp dysbiosis can be triggered by overwashing, harsh shampoos, excessive oil production, and even genetic factors like hair density or dandruff-prone skin. These disrupt the balance of good and bad microbes Dandruff is linked to reduced microbial diversity and fungal overgrowth. Studies show healthy scalps have more protective bacteria, while dandruff-prone scalps are overrun with inflammatory microbes like Malassezia restricta and Malassezia globosa Long-term relief comes from restoring beneficial microbes, not just killing fungi. Using microbiome-safe natural products, avoiding daily shampooing, and consuming foods that promote the growth of probiotics, prebiotics, and postbiotics are effective ways to rebalance your scalp naturally

This episode of Communicable takes on a special format where editors of CMI Comms, Marc Bonten, Josh Davis, Erin McCreary, Emily McDonald, all clinical trialists in their own right, take turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna. These include the CloCeBa trial on Staphylococcus aureus bacteraemia treatment options, the Taper V trial on vancomycin as prophylaxis for Clostridioides difficile infection, the ASTARTÉ trial on temocillin versus meropenem for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales, the HARVEST trial investigating high doses of rifampicin for tuberculosis meningitis, and the CAP5 trial on shortening antibiotic treatment for community-acquired pneumonia.   This episode was peer reviewed by Dr. Barbora Píšová (Czech Republic) and is the first of a two-part series covering selected clinical trials presented at ESCMID Global 2025. References: Lescure X, et al. Cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trialMcDonald EG, et al. Initial vancomycin taper for the prevention of recurrent Clostridioides difficile infection: the TAPER-V randomised controlled trialCogliati Dezza F, et al. Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trialVan Crevel R, et al. High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trialBastrup Israelsen S, et al. Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trial

Send us a textEpisódio 54 – Hipotermia, Crescimento, Infecção Metabólica e Nariz Eletrônico na NeonatologiaNeste episódio especial, apresentamos os destaques do Encontro Internacional de Neonatologia, realizado nos dias 4 e 5 de abril em Gramado, sob a mais uma vez brilhante organização dos professores Rita e Renato Procianoy. Um evento que reuniu especialistas do Brasil e do mundo para discutir os avanços mais recentes no cuidado neonatal — e nós não poderíamos deixar de compartilhar com vocês, ouvintes que acompanham quinzenalmente o nosso Journal Club em língua portuguesa.Selecionamos quatro estudos que marcaram as discussões científicas durante o encontro:1. Whole-Body Hypothermia vs Targeted Normothermia for Neonates With Mild Encephalopathy – Este ensaio clínico multicêntrico coloca em pauta uma pergunta que muitos de nós enfrentamos à beira do leito: recém-nascidos com encefalopatia leve devem ser resfriados?2. Glucose supply and glycolysis inhibition shape the clinical fate of Staphylococcus epidermidis-infected preterm newborns – Uma fascinante investigação experimental que conecta metabolismo energético e resposta inflamatória em prematuros infectados, com possíveis implicações clínicas na prevenção da disfunção orgânica.3.Monitoring the Postnatal Growth of Preterm Infants: A Paradigm Change – Este artigo propõe uma verdadeira mudança de paradigma na forma como monitoramos o crescimento de prematuros, destacando a importância de uma abordagem individualizada e centrada no bebê. 4. Longitudinal fecal microbiota and volatile metabolomics preceding necrotizing enterocolitis in preterm infants– Um estudo que combina análise do microbioma e metabolômica para identificar marcadores precoces de enterocolite necrosante, uma das doenças mais temidas da neonatologia.Esperamos que este episódio especial amplie seu repertório científico e inspire práticas ainda mais seguras e baseadas em evidências. Se você gosta do nosso conteúdo, avalie o programa na sua plataforma de streaming e compartilhe com colegas e interessados. Seu apoio é essencial para continuarmos promovendo a neonatologia em língua portuguesa!Até o próximo episódio! Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Breakpoints joins forces with CMI Communications' Communicable podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025. Hosts Drs. Erin McCreary and Angela Huttner interview SNAP trial investigators, Drs. Joshua Davis and Steven Tong, on results from penicillin-susceptible and methicillin-susceptible Staphylococcus aureus domains. Conflict of Interest for DSMC Members: Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationship that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Each DSMC candidate was well vetted.

In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steve Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groom, and peer-reviewed by Megan Klatt and Lacy Worden. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner. Literature:Steven Y. C. Tong, Joshua S. Davis, Emily Eichenberger et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015 Jul;28(3):603-61.SNAP Adaptive trial platform/results of the PSSA & MSSA domains: https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/CloCeBa trial results (ESCMID Global April 2025 presentation): www.online.escmid.org *https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/Note on access to online video of ESCMID Global presentations:In the six months following the congress:Non-ESCMID members have access if they registered for ESCMID GlobalMembers have access only if they registered for ESCMID GlobalSix months after the congress:Non-members do not have access, whatever their ESCMID Global registration statusAll members have access, whatever their ESCMID Global registration statusCAMERA 2 trial: Steven Y. C. Tong, David C. Lye, Dafna Yahav, et al. Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA BacteremiaA Randomized Clinical Trial. JAMA. 2020;323(6):527-537. doi:10.1001/jama.2020.0103 POET trial: Kasper Iversen, Nikolaj Ihlemann, Sabine U. Gill et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med 2019;380:415-424POET trial follow-up: Mia M. Pries-Heje, Christoffer Wiingaard, Nikolaj Ihlemann. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. N Engl J Med 2022;386:601-602

What exciting times! Clinical trials into the management of SAB! SNAP publication on the horizon! But how do we interpret and apply the results of these trials to our patients? This week Jame and Callum are joined by Dr Clark Russell, Clinical Lecturer in Infectious Diseases to discuss:The difficulty in interpreting current clinical trials in SAB.The emerging concept of "low risk" SAB and how to define this.The heterogeneity of SAB and how this might be exploited.Notes for this episode here: https://idiots.notion.site/107-SAB-update-1316a1ea09d8800ba701ca7ebc8d4093 Previous episodes for the basics of Staphylococcus aureus and SABATO & SNAP trials:1. It starts with Staph65. SNAP trial protocol72. SABATO trial & 73. SABATaddendumSend us a text Support the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

Do you keep relapsing after treating candida, SIBO or other conditions? The culprit behind these never-ending cycles may be biofilms. In this episode, I'll explain how biofilms form, help you identify signs that you have them, and recommend the best antibiofilm agents. Tune in!   Learn more about biofilms and improve your gut now! Reach out to our virtual clinic: https://drruscio.com/virtual-clinic/  

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the USF Morsani College of Medicine, Division of Infectious Diseases, presents a case-based discussion of gram positive organisms producing disease in humans. Infections discussed include Staphylococcus aureus, Coagulase negative Staphylococcus, Pneumococcus, Streptococcus spp., Enterococcus, Corynebacterium, Bacillus, and Erysipelothrix. Associated clinical syndromes are also discussed.

We've all felt the instant relief of scratching an itch, but what if that fleeting moment of bliss was actually doing more than just satisfying an itch? Scientists have just published new research in the journal Science which shows how scratching activates an immune response that can help protect the skin against harmful infections. Scratching has long been thought to serve a practical function: removing irritants like insects, dust, or allergens. But some itches, such as those caused by mosquito bites, persist long after the culprit is gone. This suggests that scratching might serve another purpose beyond simply removing irritants. Researchers induced an itchy allergic contact dermatitis on the ears of mice have of which were allowed to scratch the itch and half that couldn't due to wearing a tiny headcollar. The mice that were allowed to scratch developed increased swelling and a surge of immune cells called neutrophils at the site. However, the mice that were prevented from scratching, had significantly lower inflammation and fewer immune cells in the affected area. The researchers found that scratching activates pain-sensing neurons, which then release a powerful neurochemical called substance P. This messenger molecule wakes up mast cells which are immune cells that play a key role in allergic reactions. Once activated, mast cells recruit neutrophils, amplifying inflammation at the scratched site. Previously, scientists believed that mast cells were only triggered by allergens, however this study revealed an entirely new pathway: scratching itself can activate these immune responses. While this might sound like a bad thing, it turns out that it has a hidden benefit. The team discovered that scratching isn't just about relief, it also helps to keep dangerous bacteria at bay. In their experiment, they found that mice who were allowed to scratch had lower levels of the potentially harmful bacteria Staphylococcus aureus on their skin compared to those prevented from scratching. This suggests that scratching might have antibacterial effects, helping to remove harmful microbes before they cause infection. Of course, not all scratching is beneficial. Chronic scratching, as seen in conditions like eczema or diabetes, can lead to skin damage and increase the risk of infection. In these cases, the same immune response that helps in the short term can become a problem if it's constantly activated. Interestingly, researchers identified two separate nerve pathways, one that signals an itch and another that controls the immune response from scratching. This discovery opens the door to potential treatments that could block the itch-scratch cycle while preserving the immune benefits of scratching. Scientists hope that by targeting specific nerve pathways, they can develop new therapies that stop the discomfort without shutting down the body's natural immune defences. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Dr. Don - not risky

We are pleased to announce the first of a new series of upcoming episodes, titled ‘Pulse Check – Key Papers at a Glance'. Our host Can discuss two recent and impactful EJCTS articles on infective endocarditis. Joined by the renowned, Michael Borger and Torsten Doenst, we explore firstly the implications of preoperative septic cerebral embolism for patients undergoing valve surgery. Then followed by an exploration into the use of haemoadsorption therapy, addressing the key issue of controlling inflammation during cardiac surgery for endocarditis. Listen to gain rapid insight into the associated articles: Effect of haemoadsorption during cardiac surgery for Staphylococcus aureus endocarditis: a REMOVE trial post hoc analysis Outcomes following heart valve surgery in patients with infective endocarditis and preoperative septic cerebral embolism: insights from the CAMPAIGN study group'

Man Says He Visited Heaven, Met Jesus During Near-Death Experience Watch this video at- https://youtu.be/3FQmcCFZ8Ng?si=x4U0Eezqh21CuDDg CBN News 2.28M subscribers 123,685 views May 16, 2024 Randy Kay's "afterlife" experience still leaves him visibly emotional as he recounts details of visiting heaven, meeting Jesus, and returning to share his harrowing journey. Kay, author of the book, "Heaven Stormed: A Heavenly Encounter Reveals Your Assignment in the End Time Outpouring and Tribulation," told CBN News he was once a denier of near-death experience claims — until he faced his own purported heaven journey. He recalled his own afterlife experience, which began with a sore calf. At first, he thought he had strained a muscle, but while working out and going on a bike ride, his calf began to swell. "I was able to make it back home and then went to the doctor to get an anti-inflammatory prescription, and lo and behold, when I pressed my heel into the floor as the doctor had suggested, I collapsed," Kay said. "And I was rushed to the emergency room." It turns out, the pain and swelling were due to seven blood clots that had formed. He then contracted Methicillin-resistant Staphylococcus aureus (MRSA), a drug-resistant bacteria. "The doctor said I was a walking dead man," Kay said. "And then the septic shock which entered into my body caused a traffic jam in my vessels, my vascular system." The chaos landed Kay in a dire situation — one that he believes sent him to heaven. "Everything went dark initially and the next moment of recall, I was looking down on my body," he said. "I was being pulled by this light. I know that sounds cliche, almost, but it's absolutely true." Kay continued, "I was in a kind of very vague, ethereal space initially where I saw these figures in front of me, and they were warring against each other. There's no other way of putting it." After his return from his after-death experience, Kay discerned he was watching spiritual warfare play out. Regardless of what people choose to believe, Kay's physical body was dead at this point, making these memories and claims quite fascinating. "My heart had stopped," he said, noting that hospital records indicate he was clinically dead for 30 minutes and 49 seconds. During that time, Kay believes he was experiencing heaven, noting he was aware that her was himself but suddenly was seeing and visualizing the world quite differently. "I was seeing things, hearing things beyond which I would be able to do otherwise in my body," he said.

In this episode of Skin Anarchy, host Dr. Ekta welcomes Dr. Barbara Paldus, founder of Codex Labs, to explore breakthrough insights into eczema treatment. Dr. Paldus delves into the science behind the skin-gut-brain microbiome axis and explains how addressing both internal and external factors can revolutionize eczema care. Drawing on her recent TED Talk, she reveals that supporting gut health, reducing systemic inflammation, and restoring a balanced skin barrier can yield up to three times the benefits of traditional topical treatments.Dr. Paldus outlines the two main theories behind eczema—whether it starts with a leaky gut or a weakened skin barrier—and emphasizes that true relief comes from a holistic approach. She shares compelling data and real-world results from Codex Labs' innovative products, including the Bia Unscented Soap, Bia Eczema Relief Lotion, and Antü Skin Barrier Support Supplement. These products are designed to soothe, hydrate, and strengthen the skin from within, proving effective even in rigorous clinical trials.The conversation highlights the importance of understanding the genetic and environmental factors that contribute to eczema, from mutations in the filaggrin gene to the role of Staphylococcus aureus. Dr. Paldus also offers practical advice on integrating dietary changes, stress management, and gentle skincare into a comprehensive routine that supports long-term skin health.Tune in to discover how combining cutting-edge science with holistic wellness is paving the way for a new era in eczema treatment and learn why taking care of your skin from the inside out is the future of dermatology.Shop Codex's NEW Bia Eczema Relief Lotion.To learn more about Codex Labs, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Arctic air is on the move southward and eastward into the United States in the coming days and will create harsh conditions for millions prior to the end of February. Also, the "superbug bacteria" is the methicillin-resistant Staphylococcus aureus, which resists most antibiotics, causes lung scarring and could cause death. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Drs. Henry “Chip” Chambers and Warren Rose join Dr. Megan Klatt to tackle rifampin dosing for gram-positive infections. In this episode, they break down rifampin synergy studies and discuss what is the optimal dosing of rifampin for challenging gram-positive bacterial cases, in particular Staphylococcus aureus infections with or without retained hardware/devices.   Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/ References: Deconstructing the Dogma: Systematic Literature Review and Meta-analysis of Adjunctive Gentamicin and Rifampin in Staphylococcal Prosthetic Valve Endocarditis. Open Forum Infect Dis. 2022 Oct 31;9(11):ofac583. doi: 10.1093/ofid/ofac583. PMID: 36408468. Effectiveness of adjunctive rifampicin for treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2023 Oct 3;78(10):2419-2427. doi: 10.1093/jac/dkad214. PMID: 37583062. Adjunctive Rifampin Following Debridement and Implant Retention for Staphylococcal Prosthetic Joint Infection: Is it Effective if not Combined With a Fluoroquinolone? Open Forum Infect Dis. 2022 Oct 31;9(12):ofac582. doi: 10.1093/ofid/ofac582. PMID: 36504699.

Drs. Nico Cortes-Penfield (@Cortes-Penfield), Kerry LaPlante (@Kerry_LaPlante), Jessica Seidelman (@JessieLSeidel) join Dr. Julie Ann Justo (@julie_justo) to discuss the pesky slime that is biofilm in periprosthetic joint infections. They review biofilm composition & development, have an honest discussion about whether antibiotics can ever really eradicate it, and provide updates on the promising non-pharmacologic strategies on the horizon (bacteriophages, electromagnetism, & more). Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections. Breakpoints Podcast Episode #67. Society of Infectious Diseases Pharmacists. Dosing Consult: Rifampin Part 1. Breakpoints Podcast Episode #104. Society of Infectious Diseases Pharmacists. Review on Staphylococcal biofilm development: Schilcher K, Horswill AR. 2020 Aug 12;84(3):e00026-19. doi: 10.1128/MMBR.00026-19. PMID: 32792334. Antibiotics can fail to kill biofilm cells even if they penetrate the biofilm: Singh R, et al. Pathog Dis. 2016 Aug;74(6):ftw056. doi: 10.1093/femspd/ftw056. Epub 2016 Jul 7. PMID: 27402781. Subinhibitory antibiotic concentrations can promote biofilm formation: Schilcher K, et al. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5957-67. doi: 10.1128/AAC.00463-16. PMID: 27458233. Clinical and genetic risk factors for biofilm-forming Staphylococcus aureus: Luther MK, et al. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02252-17. doi: 10.1128/AAC.02252-17. PMID: 29530854. Meta-analysis showing poor clinical outcomes with debridement, antibiotics, and implant retention (DAIR): Kunutsor SK, et al. J Infect. 2018 Dec;77(6):479-488. doi: 10.1016/j.jinf.2018.08.017. PMID: 30205122. Thieme L, et al. MBEC versus MBIC: the lack of differentiation between biofilm reducing and inhibitory effects as a current problem in biofilm methodology. Biol Proced Online 21, 18 (2019). https://doi.org/10.1186/s12575-019-0106-0. Ongoing trial investigating use of MBEC in the treatment of PJIs: Tillander JAN, et al. BMJ Open. 2022 Sep 15;12(9):e058168. doi: 10.1136/bmjopen-2021-058168. PMID: 36109038. Maale, G. Complete eradication of biofilm using low frequency electromagnetic force (EMF) and antibiotics at MIC. 34th Annual Meeting Musculoskeletal Infection Society. 2024 Aug. Abstract 1232 (see full program). Meta-analysis on bacteriophages for biofilm: Kovacs CJ, et al. Mil Med. 2024 May 18;189(5-6):e1294-e1302. doi: 10.1093/milmed/usad385. PMID: 37847552. Berking BB, et al. Biofilm disruption from within: light-activated molecular drill-functionalized polymersomes bridge the gap between membrane damage and quorum sensing-mediated cell death. ACS Biomater Sci Eng. 2024 Sep 9;10(9):5881-5891. doi: 10.1021/acsbiomaterials.4c01177. PMID: 39176452. Aboelnaga N, et al. Deciphering the dynamics of methicillin-resistant Staphylococcus aureus biofilm formation: from molecular signaling to nanotherapeutic advances. Cell Commun Signal. 2024 Mar 22;22(1):188. doi: 10.1186/s12964-024-01511-2. PMID: 38519959. Conway J, et al. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0065524. doi: 10.1128/aac.00655-24. PMID: 39012102. Mulpur P, et al. Efficacy of intrawound vancomycin in prevention of periprosthetic joint infection after primary total knee arthroplasty: a prospective double-blinded randomized control trial. J Arthroplasty. 2024 Jun;39(6):1569-1576. doi: 10.1016/j.arth.2024.01.003. PMID: 38749600. Dong Y, et al. Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J Antimicrob Chemother. 2013 Apr;68(4):816-26. doi: 10.1093/jac/dks490. PMID: 23248238. Miltenberg B, et al. Intraosseous Regional Administration of Antibiotic Prophylaxis for Total Knee Arthroplasty: A Systematic Review. J Arthroplasty. 2023 Apr;38(4):769-774. doi: 10.1016/j.arth.2022.10.023. PMID: 36280158. Viswanathan VK, et al. Intraosseous regional antibiotic prophylaxis in total joint arthroplasty (TJA): Systematic review and meta-analysis. J Clin Orthop Trauma. 2024 Oct 3;57:102553. doi: 10.1016/j.jcot.2024.102553. PMID: 39435324. SOLARIO trial: Dudareva M, et al. The European Bone and Joint Infection Society Meeting, 2024 Sept. SOLARIO trial press release from BoneSupportTM. 2024 Oct 3. Fehring TK, et al. Does treatment at a specialized prosthetic joint infection center improve the rate of reimplantation. J Arthroplasty. 2023 Jun;38(6S):S314-7. PMID 37004968. ROADMAP trial website. 2024.

In this episode of the Micro Binfie Podcast, host Andrew Page takes listeners to the heart of the microbial genomics hackathon in Bethesda, Maryland, for an engaging conversation with special guest Megan Phillips, a PhD student from Emory University. Megan delves into her research on Staphylococcus aureus (MRSA), highlighting its fascinating dual nature as both a harmless and potentially serious pathogen. Megan discusses the complexities of tetracycline resistance, particularly focusing on plasmid-mediated mechanisms involving the pt181 plasmid. She explains how this plasmid's efflux pump, encoded by the gene tetK, contributes to variable resistance levels and the factors influencing MIC (Minimum Inhibitory Concentration) variability. Listeners will learn about the intricacies of plasmid copy numbers, their global spread across clonal complexes, and the occurrence of horizontal and vertical gene transfer. Throughout the episode, Megan shares insights on working with short-read sequencing data and the strategies she employs to detect plasmid presence using tools like BLAST. She also touches on the challenges and fascinating discoveries of tracking historical sample data and integrating findings from older research papers, showcasing her appreciation for the poetic style of scientific writing from the 1940s. For those interested in antimicrobial resistance, evolutionary microbiology, and the subtleties of bacterial genome analysis, this episode offers a compelling blend of technical details and engaging storytelling. Tune in to hear more about Megan's upcoming publications, her experiences navigating complex genomic data, and her thoughts on antimicrobial stewardship and historical perspectives on drug resistance.

Guest: Dr. Christian de Virgilio is the Chair of the Department of Surgery at Harbor-UCLA Medical Center. He is also Co-Chair of the College of Applied Anatomy and a Professor of Surgery at UCLA's David Geffen School of Medicine. He completed his undergraduate degree in Biology at Loyola Marymount University and earned his medical degree from UCLA. He then completed his residency in General Surgery at UCLA-Harbor Medical Center followed by a fellowship in Vascular Surgery at the Mayo Clinic.   Resources:  Rutherford Chapters (10th ed.): 174, 175, 177, 178 Prior Holding Pressure episode on AV access creation: https://www.audiblebleeding.com/vsite-hd-access/ The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access: https://www.jvascsurg.org/article/S0741-5214%2808%2901399-2/fulltext  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update: https://pubmed.ncbi.nlm.nih.gov/32778223/    Outline: Steal Syndrome Definition & Etiology Steal syndrome is an important complication of AV access creation, since access creation diverts arterial blood flow from the hand. Steal can be caused by multiple factors—arterial occlusive disease proximal or distal to the AV anastomosis, high flow through the fistula at the expense of distal arterial perfusion, and failure of the distal arterial networks to adapt to this decreased blood flow.  Incidence and Risk Factors The frequency of steal syndrome is 1.6-9%1,2, depending on the vessels and conduit choice Steal syndrome is more common with brachial and axillary artery-based accesses and nonautogenous conduits. Other risk factors for steal syndrome are peripheral vascular disease, coronary artery disease, diabetes, advanced age, female sex, larger outflow conduit, multiple prior permanent access procedures, and prior episodes of steal.3,4  Long-standing insulin-dependent diabetes causes both medial calcinosis and peripheral neuropathy, which limits arteries' ability to vasodilate and adjust to decreased blood flow. Patient Presentation, Symptoms, Grading Steal syndrome is diagnosed clinically.  Symptoms after AVG creation occurs within the first few days, since flow in prosthetic grafts tend to reach a maximum value very early after creation. Native AVFs take time to mature and flow will slowly increase overtime, leading to more insidious onset of symptoms that can take months or years. The patient should have a unilateral complaint in the extremity with the AV access. Symptoms of steal syndrome, in order of increasing severity, include nail changes, occasional tingling, extremity coolness, numbness in fingertips and hands, muscle weakness, rest pain, sensory and motor deficits, fingertip ulcerations, and tissue loss.  There could be a weakened radial pulse or weak Doppler signal on the affected side, and these will become stronger after compression of the AV outflow. Symptoms are graded on a scale specified by Society of Vascular Surgery (SVS) reporting standards:5  Workup Duplex ultrasound can be used to analyze flow volumes. A high flow volume (in autogenous accesses greater than 800 mL/min, in nonautogenous accesses greater than 1200 mL/min) signifies an outflow issue. The vein or graft is acting as a pressure sink and stealing blood from the distal artery. A low flow volume signifies an inflow issue, meaning that there is a proximal arterial lesion preventing blood from reaching the distal artery. Upper extremity angiogram can identify proximal arterial lesions. Prevention Create the AV access as distal as possible, in order to preserve arterial inflow to the hand and reduce the anastomosis size and outflow diameter.  SVS guidelines recommend a 4-6mm arteriotomy diameter to balance the need for sufficient access flow with the risk of steal. If a graft is necessary, tapered prosthetic grafts are sometimes used in patients with steal risk factors, using the smaller end of the graft placed at the arterial anastomosis, although this has not yet been proven to reduce the incidence of steal.  Indications for Treatment Intervention is recommended in lifestyle-limiting cases of Grade II and all Grade III steal cases. If left untreated, the natural history of steal syndrome can result in chronic limb ischemia, causing gangrene with loss of digits or limbs. Treatment Options Conservative management relies on observation and monitoring, as mild cases of steal syndrome may resolve spontaneously. Inflow stenosis can be treated with endovascular intervention (angioplasty with or without stent) Ligation is the simplest surgical treatment, and it results in loss of the AV access. This is preferred in patients with repetitive failed salvage attempts, venous hypertension, and poor prognoses. Flow limiting procedures can address high volumes through the AV access. Banding can be performed with surgical cutdown and placement of polypropylene sutures or a Dacron patch around the vein or graft. The Minimally Invasive Limited Ligation Endoluminal-Assisted Revision (MILLER) technique employs a percutaneous endoluminal balloon inflated at the AVF to ensure consistency in diameter while banding Plication is when a side-biting running stitch is used to narrow lumen of the vein near the anastomosis. A downside of flow-limiting procedures is that it is often difficult to determine how much to narrow the AV access, as these procedures carry a risk of outflow thrombosis. There are also surgical treatments focused on reroute arterial inflow. The distal revascularization and interval ligation (DRIL) procedure involves creation of a new bypass connecting arterial segments proximal and distal to the AV anastomosis, with ligation of the native artery between the AV anastomosis and the distal anastomosis of the bypass. Reversed saphenous vein with a diameter greater than 3mm is the preferred conduit. Arm vein or prosthetic grafts can be used if needed, but prosthetic material carries higher risk of thrombosis. The new arterial bypass creates a low resistance pathway that increases flow to distal arterial beds, and interval arterial ligation eliminates retrograde flow through the distal artery.  The major risk of this procedure is bypass thrombosis, which results in loss of native arterial flow and hand ischemia. Other drawbacks of DRIL include procedural difficulty with smaller arterial anastomoses, sacrifice of saphenous or arm veins, and decreased fistula flow. Another possible revision surgery is revision using distal inflow (RUDI). This procedure involves ligation of the fistula at the anastomosis and use of a conduit to connect the outflow vein to a distal artery. The selected distal artery can be the proximal radial or ulnar artery, depending on the preoperative duplex. The more dominant vessel should be spared, allowing for distal arterial beds to have uninterrupted antegrade perfusion. The nondominant vessel is used as distal inflow for the AV access. RUDI increases access length and decreases access diameter, resulting in increased resistance and lower flow volume through the fistula. Unlike DRIL, RUDI preserves native arterial flow.  Thrombosis of the conduit would put the fistula at risk, rather than the native artery.  The last surgical revision procedure for steal is proximalization of arterial inflow (PAI). In this procedure, the vein is ligated distal to the original anastomosis site and flow is re-established through the fistula with a PTFE interposition graft anastomosed end-to-side with the more proximal axillary artery and end-to-end with the distal vein. Similar to RUDI, PAI increases the length and decreases the diameter of the outflow conduit. Since the axillary artery has a larger diameter than the brachial artery, there is a less significant pressure drop across the arterial anastomosis site and less steal. PAI allows for preservation of native artery's continuity and does not require vein harvest.  Difficulties with PAI arise when deciding the length of the interposition graft to balance AV flow with distal arterial flow. 2. Ischemic Monomelic Neuropathy Definition Ischemic monomelic neuropathy (IMN) is a rare but serious form of steal that involves nerve ischemia. Severe sensorimotor dysfunction is experienced immediately after AV access creation. Etiology IMN affects blood flow to the nerves, but not the skin or muscles because peripheral nerve fibers are more vulnerable to ischemia. Incidence and Risk Factors IMN is very rare; it has an estimated incidence of 0.1-0.5% of AV access creations.6 IMN has only been reported in brachial artery-based accesses, since the brachial artery is the sole arterial inflow for distal arteries feeding all forearm nerves. IMN is associated with diabetes, peripheral vascular disease, and preexisting peripheral neuropathy that is associated with either of the conditions. Patient Presentation Symptoms usually present rapidly, within minutes to hours after AV access creation. The most common presenting symptom is severe, constant, and deep burning pain of the distal forearm and hand. Patients also report impairment of all sensation, weakness, and hand paralysis. Diagnosis of IMN can be delayed due to misattribution of symptoms to anesthetic blockade, postoperative pain, preexisting neuropathy, a heavily bandaged arm precluding neurologic examination. Treatment Treatment is immediate ligation of the AV access. Delay in treatment will quickly result in permanent sensorimotor loss.   3. Perigraft Seroma Definition A perigraft seroma is a sterile fluid collection surrounding a vascular prosthesis and is enclosed within a pseudomembrane. Etiology and Incidence Possible etiologies include: transudative movement of fluid through the graft material, serous fluid collection from traumatized connective tissues (especially the from higher adipose tissue content in the upper arm), inhibition of fibroblast growth with associated failure of the tissue to incorporate the graft, graft “wetting” or kinking during initial operation, increased flow rates, decreased hematocrit causing oncotic pressure difference, or allergy to graft material. Seromas most commonly form at anastomosis sites in the early postoperative period. Overall seroma incidence rates after AV graft placement range from 1.7–4% and are more common in grafts placed in the upper arm (compared to the forearm) and Dacron grafts (compared to PTFE grafts).7-9 Patient Presentation and Workup Physical exam can show a subcutaneous raised palpable fluid mass Seromas can be seen with ultrasound, but it is difficult to differentiate between the types of fluid around the graft (seroma vs. hematoma vs. abscess) Indications for Treatment Seromas can lead to wound dehiscence, pressure necrosis and erosion through skin, and loss of available puncture area for hemodialysis Persistent seromas can also serve as a nidus for infection. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines10 recommend a tailored approach to seroma management, with more aggressive surgical interventions being necessary for persistent, infected-appearing, or late-developing seromas.   Treatment The majority of early postoperative seromas are self-limited and tend to resolve on their own Persistent seromas have been treated using a variety of  methods-- incision and evacuation of seroma, complete excision and replacement of the entire graft, and primary bypass of the involved graft segment only. Graft replacement with new material and rerouting through a different tissue plane has a higher reported cure rate and lower rate of infection than aspiration alone.9     4. Infection Incidence and Etiology The reported incidence of infection ranges 4-20% in AVG, which is significantly higher than the rate of infection of 0.56-5% in AVF.11  Infection can occur at the time of access creation (earliest presentation), after cannulation for dialysis (later infection), or secondary to another infectious source. Infection can also further complicate a pre-existing access site issue such as infection of a hematoma, thrombosed pseudoaneurysm, or seroma. Skin flora from frequent dialysis cannulations result in common pathogens being Staphylococcus, Pseudomonas, or polymicrobial species. Staphylococcus and Pseudomonas are highly virulent and likely to cause anastomotic disruption. Patient Presentation and Workup Physical exam will reveal warmth, pain, swelling, erythema, induration, drainage, or pus. Occasionally, patients have nonspecific manifestations of fever or leukocytosis. Ultrasound can be used to screen for and determine the extent of graft involvement by the infection.   Treatments In AV fistulas: Localized infection can usually be managed with broad spectrum antibiotics.  If there are bleeding concerns or infection is seen near the anastomosis site, the fistula should be ligated and re-created in a clean field. In AV grafts: If infection is localized, partial graft excision is acceptable. Total graft excision is recommended if the infection is present throughout the entire graft, involves the anastomoses, occludes the access, or contains particularly virulent organisms Total graft excision may also be indicated if a patient develops recurrent bacteremia with no other infectious source identified. For graft excision, the venous end of the graft is removed and the vein is oversewn or ligated. If the arterial anastomosis is intact, a small cuff of the graft can be left behind and oversewn. If the arterial anastomosis is involved, the arterial wall must be debrided and ligation, reconstruction with autogenous patch angioplasty, or arterial bypass can be pursued. References   1. Morsy AH, Kulbaski M, Chen C, Isiklar H, Lumsden AB. Incidence and Characteristics of Patients with Hand Ischemia after a Hemodialysis Access Procedure. J Surg Res. 1998;74(1):8-10. doi:10.1006/jsre.1997.5206 2. Ballard JL, Bunt TJ, Malone JM. Major complications of angioaccess surgery. Am J Surg. 1992;164(3):229-232. doi:10.1016/S0002-9610(05)81076-1 3. Valentine RJ, Bouch CW, Scott DJ, et al. Do preoperative finger pressures predict early arterial steal in hemodialysis access patients? A prospective analysis. J Vasc Surg. 2002;36(2):351-356. doi:10.1067/mva.2002.125848 4. Malik J, Tuka V, Kasalova Z, et al. Understanding the Dialysis access Steal Syndrome. A Review of the Etiologies, Diagnosis, Prevention and Treatment Strategies. J Vasc Access. 2008;9(3):155-166. doi:10.1177/112972980800900301 5. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002;35(3):603-610. doi:10.1067/mva.2002.122025 6. Thermann F, Kornhuber M. Ischemic Monomelic Neuropathy: A Rare but Important Complication after Hemodialysis Access Placement - a Review. J Vasc Access. 2011;12(2):113-119. doi:10.5301/JVA.2011.6365 7. Dauria DM, Dyk P, Garvin P. Incidence and Management of Seroma after Arteriovenous Graft Placement. J Am Coll Surg. 2006;203(4):506-511. doi:10.1016/j.jamcollsurg.2006.06.002 8. Gargiulo NJ, Veith FJ, Scher LA, Lipsitz EC, Suggs WD, Benros RM. Experience with covered stents for the management of hemodialysis polytetrafluoroethylene graft seromas. J Vasc Surg. 2008;48(1):216-217. doi:10.1016/j.jvs.2008.01.046 9. Blumenberg RM, Gelfand ML, Dale WA. Perigraft seromas complicating arterial grafts. Surgery. 1985;97(2):194-204. 10. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4):S1-S164. doi:10.1053/j.ajkd.2019.12.001 11. Padberg FT, Calligaro KD, Sidawy AN. Complications of arteriovenous hemodialysis access: Recognition and management. J Vasc Surg. 2008;48(5):S55-S80. doi:10.1016/j.jvs.2008.08.067

I've touched on the topic of endotoxemia in past episodes of the Defiant Health podcast. In this episode, let's dive deeper into this topic that is absolutely crucial to understanding and managing SO many aspects of health, from subduing anxiety and panic, to depressive, to joint pain and skin rashes, to gastrointestinal conditions, even weight management. What is endotoxemia? Fecal microbes, so-called Gram-negative species because of the way these microbes take up stain for examination under a microscope, species such as E. coli and Salmonella, have something called lipopolysaccharide endotoxin in their cells walls. Other species, so-called Gram positive species such as Enterococcus, Staphylococcus, and Streptococcus, that stain in a different manner, have something called lipoteichoic acid in their cell walls. When these microbes die, both Gram-negative and Gram-positive, these toxic factors are released into the intestines. If these fecal microbes are confined to the colon, where they belong, a section of GI tract adapted to their presence, the entry of these toxic components are limited and current evidence is unclear in how importat this process is. The real trouble occurs, however, when fecal microbes have invaded the 24-feet of small intestine, a process we label small intetinal bacterial overgrowth, or SIBO, because the small intestine—the stomach, duodenum, jejunum, and ileum are not well-adapted to the invasion of fecal species. Here, they die, release their toxic components, which then enter the bloodstream, the process labeled endotoxemia. People with SIBO therefore have high blood levels, typically 200-400% higher, levels of endotoxin. This is how microbes in the GI Tract export their effects to all other parts of the body. So let's discuss this process and how you can take control over it to be be better able to take control over your emotions, mood, sleep, energy, weight, and numerous other aspects of health. _______________________________________________________________________________For BiotiQuest probiotics including Sugar Shift, go here.A 15% discount is available for Defiant Health podcast listeners by entering discount code UNDOC15 (case-sensitive) at checkout.*_________________________________________________________________________________Get your 15% Paleovalley discount on fermented grass-fed beef sticks, Bone Broth Collagen, low-carb snack bars and other high-quality organic foods here.* For 12% off every order of grass-fed and pasture-raised meats from Wild Pastures, go here._____________________________________________________________________________MyReuSupport the showBooks: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

We are back with more exciting IDWeek 2024 content. In this episode, Breakpoints hostesses Drs. Erin McCreary, Julie Ann Justo, Jeannette Bouchard, and Megan Klatt highlight more of our favorite sessions and posters at IDWeek, this episode is a must listen if you are an IDWeek nerd like us! References: Perret et al. Application of OpenAI GPT-4 for the retrospective detection of catheter-associated urinary tract infections in a fictitious and curated patient data set. 10.1017/ice.2023.189 Wiemken et al. Assisting the infection preventionist: Use of artificial intelligence for health care–associated infection surveillance. 10.1016/j.ajic.2024.02.007 Leekha et al. Evaluation of hospital-onset bacteraemia and fungaemia in the USA as a potential healthcare quality measure: a cross-sectional study. 10.1136/bmjqs-2023-016831 Diekema et al. Are Contact Precautions "Essential" for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus? 10.1093/cid/ciad571 Martin et al. Contact precautions for MRSA and VRE: where are we now? A survey of the Society for Healthcare Epidemiology of America Research Network. 10.1017/ash.2024.350 Browne et al. Investigating the effect of enhanced cleaning and disinfection of shared medical equipment on health-care-associated infections in Australia (CLEEN): a stepped-wedge, cluster randomised, controlled trial. 10.1016/S1473-3099(24)00399-2 Protect trial: Decolonization in Nursing Homes to Prevent Infection and Hospitalization. 10.1056/NEJMoa2215254 Aldardeer et al. Early Versus Late Antipseudomonal β-Lactam Antibiotic Dose Adjustment in Critically Ill Sepsis Patients With Acute Kidney Injury: A Prospective Observational Cohort Study. 10.1093/ofid/ofae059 Schmiemann et al. Effects of a multimodal intervention in primary care to reduce second line antibiotic prescriptions for urinary tract infections in women: parallel, cluster randomised, controlled trial. 10.1136/bmj-2023-076305 Vernacchio et al. Improving Short Course Treatment of Pediatric Infections: A Randomized Quality Improvement Trial. 10.1542/peds.2023-063691 Advani et al. Bacteremia From a Presumed Urinary Source in Hospitalized Adults With Asymptomatic Bacteriuria. 10.1001/jamanetworkopen.2024.2283 Saif et al. Clinical decision support for gastrointestinal panel testing. 10.1017/ash.2024.15 Bekker et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. 10.1056/NEJMoa2407001 Montini et al. Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial. 10.1542/peds.2023-062598 Nielsen et al. Oral versus intravenous empirical antibiotics in children and adolescents with uncomplicated bone and joint infections: a nationwide, randomised, controlled, non-inferiority trial in Denmark. 10.1016/S2352-4642(24)00133-0 Kaasch et al. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial. 10.1016/S1473-3099(23)00756-9 AMIKINHAL: Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. 10.1056/NEJMoa2310307 PROPHY-VAP: Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial. 10.1016/S2213-2600(23)00471-X AVENIR: Azithromycin to Reduce Mortality — An Adaptive Cluster-Randomized Trial. 10.1056/NEJMoa2312093 Thomas et al. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients. 10.1093/cid/ciad458 Schuster et al. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. 10.1093/cid/ciad534 Mahadeo et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. 10.1016/S1470-2045(23)00649-6 Khoury et al. Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. 10.1016/j.ajt.2024.04.009 Spec et al. MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses—A Multicenter, Open-Label, Randomized Comparative Trial. 10.1093/ofid/ofae010

In this episode of the Micro Binfie Podcast, host Andrew Page speaks with Dr. Brooke Talbot, a recent PhD graduate from Emory University, about her research on Staphylococcus aureus, with a focus on MRSA and antibiotic resistance. Brooke shares insights into her molecular epidemiology work, discussing the complexities of tracking resistant bacterial strains in clinical settings and the significance of genomic epidemiology in public health. From honeybees to foodborne outbreaks, Brooke's diverse research background offers listeners a fascinating journey through science, microbiology, and epidemiology.

On episode #67 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 10/24 – 11/6/24. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia(Nature) Bacterial Implementation of a Pharmacist-Driven Vancomycin Area Under the Concentration-Time Curve Monitoring Program Using Bayesian Modeling in Outpatient Parenteral Antimicrobial Therapy (OFID) Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin (Nature) Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis(CID) Fungal The Last of US Season 2 (YouTube) Notes from the Field: Trichophyton mentagrophytes Genotype VII — New York City, April–July 2024 (CDC MMWR) Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients(Transplant Infectious Disease) Parasitic Outcomes of kidney transplant recipients exposed to Chagas disease under Benznidazole prophylaxis(Transplant Infectious Disease) Fake Aristotle Fakely Rails Against Fighting Inequality (Sententiae Antiquae) Need for a paradigm shift in soil-transmitted helminthiasis control (PLoS Neglected Tropical Diseases) Miscellaneous IDSA Advocacy Results in Big Win for ID in 2025 Final Medicare Rule (IDSA) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Staphylococcus Epidermidis ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Drs. Cesar Arias (@SuperBugDoc) and Katie Barber join Dr. Julie Ann Justo (@julie_justo) to discuss what is hot-off-the-presses for gram-positive bacterial infections and it's a total party vibe! They review the latest news for recent and ongoing clinical trials (DOTS, DISRUPT, and SNAP trials), discuss hope for novel clinical tests of the cefazolin inoculum effect in staphylococci, and explore the fascinating changes in virulence and potential therapeutic options for the most challenging enterococci. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp References Climate Change and Antimicrobial Resistance. Editors in Conversation Podcast. American Society for Microbiology. Oct 2023. Is More Better? The Role of Combination Therapy for MRSA. Breakpoints Podcast Episode #30. Society of Infectious Diseases Pharmacists. Turner NA, et al. DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia. ESCMID Global 2024. April 2024. NCT04775953. Real-world dalbavancin observational cohort: Rebold N, et al. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. PMID: 38427289. Exebacase DISRUPT trial : Fowler VG Jr, et al. Clin Infect Dis. 2024 Jun 14;78(6):1473-1481. doi: 10.1093/cid/ciae043. PMID: 38297916. @snap_trial tweet of Breaking News. Aug 2024. Investigator Resources for the SNAP trial. Sept 2024: https://www.snaptrial.com.au/for-investigators#interim Cefazolin inoculum effect on mortality in MSSA bacteremia : Miller WR, et al. Open Forum Infect Dis. 2018 May 23;5(6):ofy123. doi: 10.1093/ofid/ofy123. PMID: 29977970. Prevalence of cefazolin inoculum effect in MSSA and modified rapid nitrocefin test for detection: Carvajal LP, et al. Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898-24. PMID: 39345182. LiaX as surrogate for cell envelope stress in Enterococus faecium: Axell-House DB, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. PMID: 38289081. Shorter is better for uncomplicated streptococcal bacteremia: Clutter DS, et al. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0022024. doi: 10.1128/aac.00220-24. PMID: 38975753. Short vs. long antibiotic duration in Streptococcus pneumoniae bacteremia: Crotty M, et al. Open Forum Infect Dis. 2024 Aug 30;11(9):ofae478. doi: 10.1093/ofid/ofae478. PMID: 39257675. This podcast is powered by Pinecast.

In this episode, I'm getting real about my gut health journey after some eye-opening results from my GI MAP stool test. We'll chat about Candida overgrowth, why it's been a total game-changer for my health, and what I'm doing to get things back on track. If you've been dealing with bloating, fatigue, or just feeling off, this episode is for you! Key Topics: MY GI MAP stool test results and who Im working with Why Does Candida Overgrow? My Symptoms: I've been dealing with a range of issues, from bloating and fatigue to skin problems and brain fog. It's been a wild Gut Dysbiosis: I found out I have low good bacteria and high Staphylococcus levels, which means my digestion isn't great. Low digestive enzymes are making it hard to absorb nutrients, leaving me feeling bloated and sluggish. Healing Protocols: I go into my healing protocols that were given to be by my functional dietician. NAKED Fitness Challenge Fitness + Wellness Coaching Apply for Private Mentorship Connect with me on Instagram

Dr. Don and Professor Ben talk about the risks from eating a properly cooked egg with a crack in it. Dr. Don - not risky

Dr. Don and Professor Ben talk about the risks drinking beer from glasses when the bottle has been inside the glass and in contact with the beer. Dr. Don - not risky

Interview with Maria Teresa García-Romero, MD, MPH, author of Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis: A Systematic Review and Meta-Analysis. Hosted by Adewole S. Adamson, MD. Related Content: Global Antimicrobial Susceptibility Patterns of Staphylococcus aureus in Atopic Dermatitis

Joya Griffin, DVM, DACVD, is an Ohio native and graduated from Cornell University College of Veterinary Medicine in 2006. While attending Cornell, she earned numerous awards, including the Dermatology Service Award for her aptitude in clinical dermatology and her research on Malassezia otitis externa. After graduation, she completed an internship at the VCA Berwyn and Aurora animal hospitals in the Chicago area, where she was awarded the Intern Abstract Award for her presentation on methicillin-resistant Staphylococcus aureus. Griffin returned to Cornell in 2007 for a residency in dermatology and, after completing her residency training program, served 1 year as an instructor of dermatology, teaching fourth-year clinical students and lecturing to underclassmen on bacterial, fungal, and immune-mediated skin diseases. Griffin became a diplomate of the American College of Veterinary Dermatology in August 2010 and joined the Animal Dermatology Group. She has a special interest in fungal and immune-mediated skin diseases, as well as feline and equine dermatology. She enjoys lecturing to fellow veterinarians, mentoring residents, and teaching the veterinary students who extern with her. Griffin also stars in the Nat Geo WILD television series Pop Goes the Vet With Dr Joya, which highlights the challenging and mysterious cases she encounters in veterinary dermatology. Griffin always strives to care for her patients as if they are her own pets and loves building a long-lasting relationship with their pet parents. Outside of work, Griffin enjoys spending time with her family and pets. She is married to Forrest Cummings, DVM, DACVIM (SAIM), a veterinary internal medicine specialist, and they have 3 children: Caden and boy/girl twins Coby and Carter. They have a kitten named Donut and 2 dogs, Guri and Magic. Griffin loves traveling, eating the delicious meals her hubby cooks for her, and working out. 

Rosemary Bartel had no idea her life was going to take a turn when she went to a hospital near her home in Chilton, Wisconsin in the United States for standard knee replacement surgery – her second such operation. She was ready to work hard to recover and return to her busy job at her Roman Catholic diocese. But Rosie developed an all-too-common infection known as MRSA—methicillin-resistant Staphylococcus aureus. It's one of the best-known examples of antimicrobial-resistant microbes, often called superbugs. The United Nations is devoting a high-level meeting to the problem in September 2024 in the hopes of getting nations to do more to fight antimicrobial resistance or AMR.Now, 15 years later, Rosie has had her leg and hip amputated because the infection got into her bones. She has suffered numerous other infections, been in comas, lost her job, lost her health insurance, and lost most of the life she had loved.“I will probably be paying hospital bills for the rest of my life,” Rosie tells One World, One Health. Rosie is one of the luckier victims of AMR. She's still alive. Five million people a year die from complications caused by these drug-resistant germs. Now, Rosie shares her story as widely as she can as part of the Patient Family Partners Network, a group of patient advocates working to improve healthcare in the United States, and the Leapfrog Group, a nonprofit patient safety advocacy organization. She's also written a book, “Rosie's Story,” about her experience with this devastating and unending infection. Listen as Rosie describes what happened to her and what she hopes to do to help stop it from happening to others

Drs. Jim Rhodes and Molly Steed join host Jeannette Bouchard to discuss all things related to optimal dosing of daptomycin. This podcast episode provides insight on why dosing matters with this antibiotic, especially with certain organisms (looking at you, E. faecium), why weight matters with dosing, and what that pesky CPK means. Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/  References: Fixed-dose daptomycin in Staphylococcus aureus: doi 10.1002/phar.4602 High dose daptomycin for VRE: doi 10.1093/cid/ciw815 This podcast is powered by Pinecast.

On episode #61 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/1/20 - 8/14/24.  Host: Daniel Griffin and Sara Dong  Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral nPEP quick guide (AIDS Education & Training Center Program) Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide PREP after sexual assault (OFID) Adopting Early Testing for Perinatal Hepatitis C (Journal of Pediatric Infectious Diseases Society) Bacterial Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis (OFID) Trimethoprim-Sulfamethoxazole for Staphylococcus Aureus Bacteremia Prophylaxis in Patients on Hemodialysis (OFID) Human monocytotropic ehrlichiosis(PLoS Neglected Tropical Diseases) Human granulocytotropic anaplasmosis (PLoS Neglected Tropical Diseases) Bifidobacterium and Lactobacillus Probiotics for Preterm Infants (JAMA Network: JAMA Pediatrics) Rapid Implementation of Blood Culture Stewardship (CID) BD BACTEC Blood Culture Bottle Shortage - (IDSA) Fungal The Last of US Season 2 (YouTube) Clinical characteristics and mortality risks among critically ill patients with culture-proven coccidioidomycosis(OFID) Poor Clinical and Microbiologic Outcomes in C. auris Bloodstream Infection (CID) Parasitic Soap is lethal for Schistosoma mansoni cercariae (PLoS Neglected Tropical Diseases) Treatment of uncomplicated hepatic cystic echinococcosis (Cochrane Library) Blood exposure to Babesia microti(Cambridge Core) Miscellaneous Absence of Cerebrospinal Fluid Pleocytosis in Encephalitis (CID) Encephalitis due to Infection with Normocellular Cerebrospinal Fluid (CID) Podoconiosis and mental health (PLoS Neglected Tropical Diseases) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

This StAR episode features the CID State-of-the-Art Review on Staphylococcus aureus bacteremia - controversies in clinical practice.Our guest stars this episode are: Daniel Minter (UCSF)Sarah Doernberg (UCSF)Journal article link: Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clin Infect Dis. 2023 Nov 30;77(11):e57-e68. doi: 10.1093/cid/ciad500. PMID: 37950887.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/11/1489/7453594From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Have you tried using topical zinc for eczema, psoriasis, or other rashes yet? Because spoiler: when you use the correct form of zinc topically, it can be a game changer for your skin rash. Why? So many skin rash warriors are deficient in this crucial mineral. And taking zinc orally just doesn't always cut it for most people, unfortunately.So if you haven't yet explored the skin rash-zinc connection, let's take a look at why topical zinc can be so helpful, things you need to watch out for when using it, and what to look for in a topical zinc formula — because not all zinc is created the same.Before we dive in: Are you tired of chasing skin rash remedies that seem to work for everyone else but you? Do you find something that seems to help…only to have your fleeting victory erased by a massive flare? This happens because everyone's root cause of their rash is different — and most people have several root causes going on at once. So when you get one fire under control, another pops up. It's exhausting.Here's the exact process I take my private clients through to help them heal: my FREE Skin Rash Root Cause Finder. A quick and easy-to-use workbook that will help you narrow down the underlying causes of your rash so you can get to work stopping it! Download it here and let's figure this out, together! In This Episode:What are the topical zinc benefits for skin rashes?If you have a skin rash, does that mean you have a zinc deficiency?Is zinc good for eczema?Should you use nano or non-nano zinc oxide?Drawbacks of topical zinc and why you might not want to use itReal zinc and eczema resultsQuotes“There was also a statistically significant decrease in the occurrence of Staphylococcus aureus in the wounds of study participants, suggesting zinc could have anti-microbial properties.”“Generally, we often see a relationship between lower levels of zinc in the body and eczema (and other skin complications like hidradenitis suppurativa, acne, rosacea, seborrheic dermatitis, psoriasis, vitiligo, and melasma)”LinksHealthy Skin Show ep. 169: Why Is Zinc So Important For Your Skin?Healthy Skin Show ep. 172: Why Use Zinc Cream For Skin RashesDermaQuell Z+ Rebuilder – https://www.quellshop.com/products/z-rebuilderALSO – we offer all three full 2oz jars in the Ultimate Quell kit – https://www.quellshop.com/products/ultimate-quell-kitUse coupon code QUELL10 to get $10 off your first orderOR try the Quell skincare sample pack that includes Z+ Rebuilder along with Daily Butter and Nourish Butter creams for only $12.95 (free shipping) - https://www.quellshop.com/products/dermaquell-skincare-sample-kit (especially great for those who are nervous to purchase a full product without trying it first. Each sample is a sealed 0.26oz sachet packet and includes a $12.95 store credit to use on anything in the shop).